ADG206
Phase 1Active 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors
Conditions
Advanced/Metastatic Solid Tumors
Trial Timeline
Feb 13, 2023 โ Aug 30, 2026
NCT ID
NCT05614258About ADG206
ADG206 is a phase 1 stage product being developed by Adagene for Advanced/Metastatic Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05614258. Target conditions include Advanced/Metastatic Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05614258 | Phase 1 | Active |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors